Esophageal irritation due to alendronate sodium tablets - Possible mechanisms

被引:100
作者
Peter, CP [1 ]
Handt, LK [1 ]
Smith, SM [1 ]
机构
[1] Merck Res Labs, West Point, PA 19486 USA
关键词
bisphosphonate; gastrointestinal irritation;
D O I
10.1023/A:1018894827961
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Animal studies were done using an in vivo dog model to examine the possible mechanism for the esophageal adverse events reported with alendronate sodium tablets. These studies showed that under low pH conditions alendronate sodium can cause esophageal irritation. No esophageal irritation occurred at pH 3.5 or higher where the drug exists primarily as the sodium salt. The animal studies also showed that alendronate sodium can exacerbate preexisting esophageal damage. Exposure of the esophageal mucosa for a prolonged period to alendronate sodium tablet can also cause mild esophageal irritation. These findings suggest that the esophageal irritation in patients taking Fosamax can be from prolonged contact with the tablet, reflux of acidic gastric contents with alendronate sodium, and exacerbation of preexisting esophageal damage. The findings also suggest that other bisphosphonates can cause esophageal injury under similar conditions.
引用
收藏
页码:1998 / 2002
页数:5
相关论文
共 10 条
[1]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[2]  
BOZYMSKI EM, 1995, TXB GASTROENTEROLOGY, V1, P1283
[3]   Esophagitis associated with the use of alendronate [J].
deGroen, PC ;
Lubbe, DF ;
Hirsch, LJ ;
Daifotis, A ;
Stephenson, W ;
Freedholm, D ;
PryorTillotson, S ;
Seleznick, MJ ;
Pinkas, H ;
Wang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) :1016-1021
[4]   EFFECT OF ORAL ALENDRONATE ON BONE-MINERAL DENSITY AND THE INCIDENCE OF FRACTURES IN POSTMENOPAUSAL OSTEOPOROSIS [J].
LIBERMAN, UA ;
WEISS, SR ;
BROLL, J ;
MINNE, HW ;
QUAN, H ;
BELL, NH ;
RODRIGUEZPORTALES, J ;
DOWNS, RW ;
DEQUEKER, J ;
FAVUS, M ;
SEEMAN, E ;
RECKER, RR ;
CAPIZZI, T ;
SANTORA, AC ;
LOMBARDI, A ;
SHAH, RV ;
HIRSCH, LJ ;
KARPF, DB .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (22) :1437-1443
[5]   PAMIDRONATE - AN UNRECOGNIZED PROBLEM IN GASTROINTESTINAL TOLERABILITY [J].
LUFKIN, EG ;
ARGUETA, R ;
WHITAKER, MD ;
CAMERON, AL ;
WONG, VH ;
EGAN, KS ;
OFALLON, WM ;
RIGGS, BL .
OSTEOPOROSIS INTERNATIONAL, 1994, 4 (06) :320-322
[6]  
OLOVSON SG, 1983, ACTA PHARMACOL TOX, V53, P385
[7]  
*PROCT GAMBL PHARM, 1996, PHYS DESK REF, P1984
[8]   ORAL TILUDRONATE - PHARMACOLOGICAL PROPERTIES AND POTENTIAL USEFULNESS IN PAGETS-DISEASE OF BONE AND OSTEOPOROSIS [J].
REGINSTER, JYL .
BONE, 1992, 13 (05) :351-354
[9]  
RYRFELDT A, 1990, ACTA PHYSIOL SCAND, V140, P73
[10]  
SAUNDERS RL, 1977, SOUTHERN MED J, V70, P1327